

P7 U 6 JUL 2020 Date PTC Ref. No. Epsalo6 | 1130 04

TO: All Participants of Tender no. ICB/FW/PSA6/MOH-GF-ARV/PH/01/20

Dear Sirs,

Ref: - Ammended Tender Result

Re-assessment of the above captioned tender is done based on the Global Fund confirmation of pre-qualified manufacturers and please find the attached award list.

Any question related to the assessment could be forwarded to Pharmaceutical Supply Agency (PSA) Director General Office from July 06, 2020, to July 10, 2020; 8:30AM -12:30 PM and 1:30 PM- 5:30 PM.

Moreover, bidders with 2nd and 3rd least price kindly requested to submit your consent confirmation letter till 10 July, 2020 to supply the allocated qunatity with by first winner price. The one who fails to do so could be considered as unwilling to accept the allocated Quantity.

With Best Regards, Binagde Medical

ENC: 2 pagelow


CC

Director General

Deputy Director General /Procurement/

Pharmacutica Procurement Team/Program/ PSA Turnetweyesse





Document No: OF/TM/ HO-15

Effective date: 13/09/2019

Page 1 of 1

Rev. No.: 0

Tender no, ICB/FW/PSA6/MOH-GF-ARV/PH/01/20

	2						
	Lamivudine + Efavirenz + Tenofovir DF (TLE) – (300mg + 400mg + 300mg) - Tablet						
	30						
	1,419,857						
	Macleod	Mylan Lab	Laurus labs	Supplier			
	India	India	India	Winner Supplier Country			
	USD	USD	USD	Currency			
9	5.51	5.41	5.40	Currency Unit FOB price allocated Payment Term			
	212,979 LC	354,964 CA	851,914	allocated quantity			
	010	CAD	851,914 CAD/LC	Payment Term			
The second secon	Mumbai,Del hi	Mumbai	Hyderabad air or vishakapatnam sea Port	port of shipment			
	Within 90 days after LC opening 3rd least price	Within 90 days afterCAD reservation date	Within 90 days after LC opening date or CAD reservation date	Delivery Time Remark			
	3rd least price	2nd least price	Winner price	Remark			

2		item No								
Lamivudine + Efavirenz + Tenofovir DF (TLE) – (300mg + 400mg + 300mg) - Tablet		Prdoduct Description	Te	At Maril 187 M	罗方					
Mylan	Macleod	Laurus labs	Name of competitor suppliers	Tender no,:ICB/FW/PSA6/MOH-GF-ARV/PH/01/20	Reasons for Rejection	Title:	Ethiopian Pharmaceuticals	<i>የኢትዮጵያመ</i> ደሃኒትአቅራቢኤጀንሲ	Company Name:	
		Winner	Status	PSA6/MOH-G	Rejection			<i>አቅራ</i> ቢኤጀንሲ		
price incomptence	price incomptence		reason of unsuccessfulness(i f it is unsuccessful)	F-ARV/PH/01/20	Rev. No.: 0	Effective date: 13/09/2019		Document No: OF/TM/ HO-17		
			Remark		Page 1 of 1	/09/2019		TM/HO-17		

እባክዎ በዚህ ሰነድ ከመጠቀም**ዎ በፊት ትክከለ**ኛ መሆኑን ያረ*ጋግ*ጡ

Make sure that this is the correct issue before use

OF for Financial
Evaluation, OF/TM/HO-14
0, 13/09/2019